<DOC>
	<DOCNO>NCT02988024</DOCNO>
	<brief_summary>The object study assess relative bioavailability ( BA ) 80 mg LY03005 oral tablet compare 50 mg PristiqÂ® oral tablet single oral intake fast condition healthy subject 18 50 year age .</brief_summary>
	<brief_title>Pilot BA Study New LY03005 v Pristiq</brief_title>
	<detailed_description>Twenty ( 20 ) eligible subject enrol assign either LY03005 group Pristiq group 1:1 ratio one site USA .</detailed_description>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>1 . Are capable give informed consent comply study procedure ; 2 . Male female subject age 18 50 year ; 3 . Considered healthy Principal Investigator , base detailed medical history , full physical examination , clinical laboratory test , 12lead ECG vital sign ; 4 . Nonsmoker , define smoke used form tobacco 6 month screen base subject report ; 5 . Body mass index ( BMI ) 19 30 kg/m 2 inclusive body weight less 50 kg ; 6 . Willing able adhere study restriction confine clinical research center . 7 . All female subject matter age must negative pregnancy test result screen . In addition , female subject must meet one follow three condition : ( ) postmenopausal least 2 year , ( ii ) surgically sterile base subject report , ( iii ) childbearing potential , practice agree practice effective method birth control use acceptable method contraception . Acceptable method birth control include oral , injected , vaginal patch contraceptive , IUD ( Intrauterine device ) ( copper intrauterine device ) , double barrier method ( e.g. , condom , diaphragm cervical cap spermicidal foam , cream , gel suppository ) . Acceptable method birth control must use least 14 day prior use study drug , study within one month end study . 1 . Clinically significant past history gastrointestinal , cardiovascular , musculoskeletal , endocrine , hematologic , psychiatric , renal , hepatic , bronchopulmonary , neurologic , immunologic , lipid metabolism disorder , ophthalmological , drug hypersensitivity ; 2 . History suicide attempt past 12 month and/or see investigator significant history risk suicide homicide ; 3 . History presence malignancy adequately treat basal cell skin cancer ; 4 . Clinically relevant illness within one month prior screen visit screen visit may interfere conduct study ; 5 . Subjects mean systolic blood pressure three measurement &gt; 140 mmHg , mean diastolic blood pressure three measurement &gt; 90 mmHg screening ; 6 . Positive blood screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ; 7 . A history seizure . However , history febrile seizure allow ; 8 . A hospital admission major surgery within 30 day prior screen ; 9 . Participation investigational drug trial within 30 day prior screen ; 10 . A history prescription drug abuse , illicit drug use within 6 month prior screen ; 11 . A history alcohol abuse accord medical history within 6 month prior screen ; 12 . A positive screen alcohol , drug abuse ; 13 . Tobacco use within 6 month prior screen base subject report ; 14 . Subjects hypersensitivity PRISTIQ medicine contain desvenlafaxine precursor venlafaxine ; 15 . Subjects participate previous clinical study either LY03005 PRISTIQ medicine contain desvenlafaxine precursor , venlafaxine within 30 day prior screen ; 16 . An unwillingness inability comply food beverage restriction study participation ; 17 . Donation blood collection 1 unit ( approximate 450 mL ) blood ( blood product ) acute loss blood 90 day prior screen ; 18 . Use prescription overthecounter ( OTC ) medication , herbal ( include St John 's Wort , herbal tea , garlic extract ) within 14 day prior dose ( Note : Use acetaminophen &lt; 3g/day permit 24 hour prior dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>